SPRB News and Press, Spruce Biosciences Inc.

2026-02-19 06:15:30 ET H.C. Wainwright analyst issues BUY recommendation for SPRB on February 19, 2026 11:07AM ET. The previous analyst recommendation was Buy. SPRB was trading at $53.48 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Cu...

Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement Spru...

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participa...

Treatment with Weekly TA-ERT Demonstrated Rapid and Durable Normalization of Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), a Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit TA-ERT Treatment Stabilized and Preserved Cognitive and Non-Cognitive Outcom...

Daven Mody, Pharm.D., Appointed as Senior Vice President, Regulatory and Quality Bruno Gagnon, B.Pharm., M.Sc., Appointed as Senior Vice President, Clinical Development Operations Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused o...

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme re...

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration PR Newswire CAMBRIDGE, Mass. , ROTTERDAM, Netherlands and SHANGHAI , Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to...

Initial Funding of $15 Million from the First of Four Tranches, Extending Cash Runway into 2027 Facility Will Support Advancement and Potential Launch of TA-ERT for the Treatment of MPS IIIB Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical compa...

Keli Walbert brings decades of commercial leadership experience and a proven track record of successful product launches in rare disease Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurol...

2025-11-11 07:07:19 ET from JMP Securities issued a price target of $259.00 for SPRB on 2025-11-11 10:52:57. The adjusted price target was set to $259.00. At the time of the announcement, SPRB was trading at $115.61. The overall price target consensus is at $207.00 with ...